Current vascular pharmacology最新文献_第5页

Where to Next after BASIL-2 and BEST-CLI? BASIL-2 和 BEST-CLI 之后的下一步是什么？

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611351084240916052920

Kosmas I Paraskevas, Frank J Veith

引用次数: 0

New Insight into the Role of Vitamin D in the Stroke Risk: A Meta-Analysis of Stratified Data by 25(OH)D Levels. 维生素 D 对中风风险作用的新认识：按 25(OH)D 水平进行分层数据的 Meta 分析。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611331890241007112502

Maria Fusaro, Raffaele De Caterina, Giovanni Tripepi

{"title":"New Insight into the Role of Vitamin D in the Stroke Risk: A Meta-Analysis of Stratified Data by 25(OH)D Levels.","authors":"Maria Fusaro, Raffaele De Caterina, Giovanni Tripepi","doi":"10.2174/0115701611331890241007112502","DOIUrl":"10.2174/0115701611331890241007112502","url":null,"abstract":"Mendelian Randomization (MR) studies have emerged as a powerful tool for investigating causal relationships between modifiable risk factors and clinical outcomes, using genetic variants as instrumental variables. In the context of vitamin D research, MR is a promising approach to elucidate the effects of vitamin D on various health outcomes, including adverse cardiovascular events. However, the validity of MR analyses relies heavily on the strength of the genetic associations found. \"Weak instrument bias\", arising from instruments with low explanatory power for the exposure of interest, can lead to biased estimates and compromise causal inference. We have, herein, briefly reviewed the challenges posed by weak instrument bias in a large MR study on vitamin D [25(OH)D] and stroke, exploring implications for the study's validity and reliability of findings. We have then added an original meta-analysis stratified by 25(OH)D levels. By using aggregated data from a recent MR study, an original meta-analysis stratified by population mean levels of 25(OH)D has indicated that interventions based on vitamin D supplementations in population mean levels ranging from 50 to 70 nmol/L are likely to translate into a 13% reduction of stroke risk (pooled odds ratio=0.873, 95% CI: 0.764-0.997, p-value=0.04). MR studies are a valuable approach for discerning causal relationships between exposures, such as vitamin D, and health outcomes. However, the effectiveness of MR analyses depends on the robustness of the genetic instruments employed. By recognizing and addressing weak instrument bias in MR studies of vitamin D, researchers can enhance the credibility and utility of causal inference in understanding the health effects of this essential nutrient. A metaanalysis stratified by population mean levels of 25(OH)D has revealed the potential benefits of targeted interventions with vitamin D supplementations for stroke.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"67-72"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142388849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial. Sarpogrelate 对改善外周动脉疾病 (PAD) 患者和/或有 PAD 风险的患者症状的有效性和安全性：单臂、多中心、开放标签试验。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611285172241015074050

Jong Chul Won, Tae-Jin Song, Jae Hyoung Park, Hee-Tae Kim, Kyong Hoon Lee, Keun Yong Park, Ho-Seung Jeong, Ung Jeon, Kyung Wan Min, Soo Lim

{"title":"Efficacy and Safety of Sarpogrelate on Symptom Improvement in Patients with Peripheral Arterial Disease (PAD) and/or Being at Risk of PAD: A Single Arm, Multi-Centered, Open-Label Trial.","authors":"Jong Chul Won, Tae-Jin Song, Jae Hyoung Park, Hee-Tae Kim, Kyong Hoon Lee, Keun Yong Park, Ho-Seung Jeong, Ung Jeon, Kyung Wan Min, Soo Lim","doi":"10.2174/0115701611285172241015074050","DOIUrl":"10.2174/0115701611285172241015074050","url":null,"abstract":"Aims: To assess the efficacy and safety of sarpogrelate (300 mg) for symptom improvement in patients having peripheral arterial disease (PAD) and/or being at risk of PAD in clinical practice using the Peripheral Artery Questionnaire (PAQ).Background: Symptomatic changes with antiplatelets in patients with PAD are limited.Objective: To determine the effect and safety of sarpogrelate on the PAQ at 24 weeks from baseline.Methods: A total of 1003 patients having PAD and/or being at risk of PAD from 17 tertiary hospitals in South Korea who were treated with sarpogrelate, were enrolled in this study. PAQs were collected at baseline and at 12 and 24 weeks, together with physical examination and vital signs measurements. Lifestyle pattern was also investigated.Results: The average PAQ Summary Score in the efficacy evaluation analysis group significantly improved from 62.9 ± 23.7 at baseline to 68.9 ± 21.7 at 24 weeks (P<0.0001). Physical limitation items significantly improved from 69.5 ± 30.0 at baseline to 72.9 ± 28.3 after 24 weeks (P=0.0011). Symptom stability also significantly improved from 52.1 ± 21.6 at baseline to 63.6 ± 22.9 after 24 weeks (P<0.0001). Symptoms, treatment satisfaction, quality of life, and social limitation domains all improved after treatment. A total of 201 patients reported adverse events (20.0%), not directly associated with treatment.Conclusion: Treatment with 300 mg (orally) of sarpogrelate demonstrated statistically significant improvements in all domains and for the summary score of the PAQ at 24 weeks, it gave good results in terms of safety. Sarpogrelate may be helpful in reducing symptoms related to PAD.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"45-56"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142496970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic Dysfunction-associated Steatohepatitis and Cardiovascular Disease Prevention - Is Resmetirom Useful? 代谢功能障碍相关性脂肪性肝炎与心血管疾病的预防：Resmetirom 有用吗？

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611340703240809044916

Sanja Borozan, Snezana Vujosevic, Dimitri P Mikhailidis, Emir Muzurovic

引用次数: 0

Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease. 对致编辑的信的回应：罕见的内分泌紊乱和外周动脉疾病。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611372375241125111238

Mojca Jensterle, Ales Blinc, Dimitri P Mikhailidis, Panagiotis Anagnostis, Gerit-Holger Schernthaner, Pier Luigi Antignani, Katica Bajuk Studen, Miso Sabovic, Pavel Poredos

引用次数: 0

Energy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy. 心肌梗死中的能量代谢失调：缺血性心肌病的综合分析》。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611289159240724114844

Zongtao Wang, Zhixin Xie, Tudi Li, Rong Chen, Zhihuan Zeng, Jun Guo

{"title":"Energy Metabolism Dysregulation in Myocardial Infarction: An Integrative Analysis of Ischemic Cardiomyopathy.","authors":"Zongtao Wang, Zhixin Xie, Tudi Li, Rong Chen, Zhihuan Zeng, Jun Guo","doi":"10.2174/0115701611289159240724114844","DOIUrl":"10.2174/0115701611289159240724114844","url":null,"abstract":"Background: Myocardial metabolism is closely related to functional changes after myocardial infarction (MI).Objective: This study aimed to present an integrative examination of human ischemic cardiomyopathy.Methods: We used both GSE121893 single-cell suspension sequencing and GSE19303 transcription microarray data sets from the GEO database, along with a murine MI model for full-spectrum metabolite detection. Through a systematic investigation that involved differential metabolite identification and functional enrichment analysis, we shed light on the pivotal role of energy metabolism dysregulation in the progression of MI.Results: Our findings revealed an association between the core regulatory genes CDKN1A, FOS, ITGB4, and MAP2K1 and the underlying pathophysiology of the disease. These genes are identified as critical elements in the complex landscape of myocardial ischemic disorder, highlighting novel insights into therapeutic targets and the intricate biological mechanisms involved.Conclusion: This analysis provides a framework for future research on the metabolic alterations associated with MI.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"57-66"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12079314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rare Endocrine Disorders and Peripheral Arterial Disease. 罕见内分泌失调和外周动脉疾病。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611357349240925071626

Vasileios Papaioannou, Paraskevi Tsiantoula

引用次数: 0

Emotional Stress in Cardiac and Vascular Diseases. 心血管疾病中的情绪压力。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2025-01-01 DOI: 10.2174/0115701611328094241104062903

Theodora A Manolis, Antonis A Manolis, Antonis S Manolis

{"title":"Emotional Stress in Cardiac and Vascular Diseases.","authors":"Theodora A Manolis, Antonis A Manolis, Antonis S Manolis","doi":"10.2174/0115701611328094241104062903","DOIUrl":"https://doi.org/10.2174/0115701611328094241104062903","url":null,"abstract":"Introduction/objective: Emotional, mental, or psychological distress, defined as increased symptoms of depression, anxiety, and/or stress, is common in patients with chronic diseases, such as cardiovascular (CV) disease (CVD).Methods: Literature was reviewed regarding data from studies and meta-analyses examining the impact of emotional stress on the occurrence and outcome of several CVDs (coronary disease, heart failure, hypertension, arrhythmias, stroke). These influences' pathophysiology and clinical spectrum are detailed, tabulated, and pictorially illustrated.Results: This type of stress is a newly recognized risk and prognosticator for CVD including coronary artery disease, heart failure, hypertension, cardiac arrhythmias, and stroke, independently of conventional risk factors. It can impact CV outcomes, and also affect health care utilization, with more patient visits to health care facilities. The biological systems activated by mental stress comprise the sympathetic nervous system (SNS), the renin-angiotensin system (RAS), and the hypothalamic- pituitary-adrenal (HPA) axis, while several other biological processes are disrupted, such as endothelial function, inflammatory responses, oxidative stress, mitochondrial function and the function of the amygdala which is the central nervous system processing center of emotions and emotional reactions.Conclusion: Emotional stress that aggravates symptoms of depression, anxiety, and/or perceived mental stress is common in patients with chronic diseases, such as CVD. It is a newly recognized risk and prognosticator for several CVDs. It can influence CV outcomes, and also affect health care utilization. The biological systems activated by mental stress comprise the SNS, the RAS, and the HPA axis, while several other biological processes are disrupted.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modulation of Angiogenesis through Endogenous Leptin Signalling: Network Pharmacology and Resonant Recognition Model Approaches in Cardiovascular Therapy. 通过内源性瘦素信号调节血管生成：心血管治疗中的网络药理学和共振识别模型方法。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-12-26 DOI: 10.2174/0115701611370569241221155617

Tuhin Mukherjee, Satyajit Mohanty, Nayan Gupta, Nikita Nayak, Ashok Pattnaik, Sitanshu Sekhar Sahu

引用次数: 0

The Systemic Immune Inflammation Index as a Novel Predictive Biomarker for Contrast-Induced Acute Kidney Injury Risk Following Percutaneous Coronary Intervention: A Meta-Analysis of Cohort Studies. 系统免疫炎症指数作为经皮冠状动脉介入术后对比度诱发急性肾损伤风险的新型预测生物标志物：队列研究的 Meta 分析。

IF 2.8 3区医学

Current vascular pharmacology Pub Date : 2024-11-05 DOI: 10.2174/0115701611328810241028112700

Yongqiang Zhang, Yong Xie, Chunyu Zhang, Jianglin Wang, Bin Liao, Jian Feng

{"title":"The Systemic Immune Inflammation Index as a Novel Predictive Biomarker for Contrast-Induced Acute Kidney Injury Risk Following Percutaneous Coronary Intervention: A Meta-Analysis of Cohort Studies.","authors":"Yongqiang Zhang, Yong Xie, Chunyu Zhang, Jianglin Wang, Bin Liao, Jian Feng","doi":"10.2174/0115701611328810241028112700","DOIUrl":"10.2174/0115701611328810241028112700","url":null,"abstract":"Background: Contrast-induced Acute Kidney Injury (CI-AKI) frequently occurs as a complication following PCI, making the identification of high-risk patients challenging. While the systemic immune inflammation index (SII) might aid in predicting CI-AKI, the current evidence remains insufficient.Methods: We conducted a systematic literature search using PubMed, Web of Science, Embase, and the Cochrane Library, with a cut-off date of 3/20/2024. We included observational studies that examined the predictive value of SII for the risk of CI-AKI.Results: This meta-analysis encompassed 8 studies with a combined total of 6301 participants. Results showed pooled sensitivity and specificity of 0.73 (95% CI 0.69-0.76) and 0.68 (95% CI 0.57- 0.77), respectively. The sROC curve analysis indicated an AUC of 0.74 (95% CI 0.70-0.78). The risk of publication bias was low (p = 0.18).Conclusion: The results of this study suggest that SII has a relatively high sensitivity and could function as a biomarker for the prediction of CI-AKI risk in people receiving PCI treatment.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142589750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0